Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A man with abdominal pain: enough evidence for surgery?
Bolstad N, Kazaryan AM, Revheim ME, Distante S, Johnsrud K, Warren DJ, Nustad K, Edwin B. Bolstad N, et al. Clin Chem. 2012 Aug;58(8):1187-90. doi: 10.1373/clinchem.2011.167015. Clin Chem. 2012. PMID: 22843812 No abstract available.
Heterophilic antibody interference in immunometric assays.
Bolstad N, Warren DJ, Nustad K. Bolstad N, et al. Best Pract Res Clin Endocrinol Metab. 2013 Oct;27(5):647-61. doi: 10.1016/j.beem.2013.05.011. Epub 2013 Jun 20. Best Pract Res Clin Endocrinol Metab. 2013. PMID: 24094636 Review.
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.
Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R. Paur I, et al. Among authors: bolstad n. Clin Nutr. 2017 Jun;36(3):672-679. doi: 10.1016/j.clnu.2016.06.014. Epub 2016 Jun 30. Clin Nutr. 2017. PMID: 27406859 Free article. Clinical Trial.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Among authors: bolstad n. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.
Glintborg B, Kringelbach T, Bolstad N, Warren DJ, Eng G, Sørensen IJ, Loft AG, Hendricks O, Hansen I, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen DV, Goll GL, Høgdall E, Gehin J, Enevold C, Nielsen CH, Krogh NS, Johansen JS, Hetland ML. Glintborg B, et al. Among authors: bolstad n. Scand J Rheumatol. 2018 Sep;47(5):418-421. doi: 10.1080/03009742.2017.1376110. Epub 2018 Jan 9. Scand J Rheumatol. 2018. PMID: 29310493 No abstract available.
Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease.
Carlsen A, Omdal R, Leitao KØ, Isaksen K, Hetta AK, Karlsen LN, Aabakken L, Bolstad N, Warren D, Lundin KEA, Grimstad T. Carlsen A, et al. Among authors: bolstad n. Therap Adv Gastroenterol. 2018 Mar 14;11:1756284818759930. doi: 10.1177/1756284818759930. eCollection 2018. Therap Adv Gastroenterol. 2018. PMID: 29623105 Free PMC article.
70 results